Seguir
Julien Fleurence
Julien Fleurence
Dirección de correo verificada de bcm.edu
Título
Citado por
Citado por
Año
Glypican-3–specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma
SA Batra, P Rathi, L Guo, AN Courtney, J Fleurence, J Balzeau, RS Shaik, ...
Cancer immunology research 8 (3), 309-320, 2020
1602020
Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside
J Fleurence, D Cochonneau, S Fougeray, L Oliver, F Geraldo, M Terme, ...
Oncotarget 7 (27), 41172, 2016
632016
Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
J Fleurence, S Fougeray, M Bahri, D Cochonneau, B Clémenceau, ...
Journal of immunology research 2017, 2017
342017
Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development
A Desselle, T Chaumette, MH Gaugler, D Cochonneau, J Fleurence, ...
PloS one 7 (11), e45423, 2012
282012
Impairing temozolomide resistance driven by glioma stem‐like cells with adjuvant immunotherapy targeting O‐acetyl GD2 ganglioside
J Fleurence, M Bahri, S Fougeray, S Faraj, S Vermeulen, E Pinault, ...
International Journal of Cancer 146 (2), 424-438, 2020
262020
Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside
S Faraj, M Bahri, S Fougeray, A El Roz, J Fleurence, J Véziers, MD Leclair, ...
Oncoimmunology 7 (1), e1373232, 2018
172018
O-acetylated gangliosides: Structure, biosynthesis, immunogenicity, functions and their potential for cancer immunotherapy
S Fougeray, J Fleurence, S Faraj, M Bahri, D Cochonneau, M Terme, ...
Journal of Cancer Research and Therapeutics 4 (3), 21-30, 2016
62016
Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
S Birklé, A Desselle, T Chaumette, MH Gaugler, D Cochonneau, ...
Oncoimmunology 2 (4), e23700, 2013
62013
Potentiation of anticancer antibody efficacy by antineoplastic drugs: detection of antibody-drug synergism using the combination index equation
M Bahri, J Fleurence, S Faraj, MBM Daho, S Fougeray, S Birklé
JoVE (Journal of Visualized Experiments), e58291, 2019
52019
A phase 1 clinical trial using armored GPC3-car T cells for children with relapsed/refractory liver tumors
DHM Steffin, N Ghatwai, S Batra, JJ Fleurence, P Rathi, AN Courtney, ...
MOLECULAR THERAPY 28 (4), 212-213, 2020
12020
Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugs
S Birkle, J Fleurence, S Faraj, JM Le Doussal, D Cochonneau, M Terme, ...
US Patent App. 18/321,094, 2023
2023
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
S Birkle, J Fleurence, S Faraj, JM Le Doussal, D Cochonneau, M Terme, ...
US Patent 11,697,689, 2023
2023
Glypican-3-Specific CAR NKT Cells Armored with IL-15 Mediate Potent Anti-Tumor Response Against Hepatocellular Carcinoma
R Shaik, P Rathi, N Schneller, T Nguyen, L Guo, A Courtney, J Fleurence, ...
MOLECULAR THERAPY 28 (4), 34-35, 2020
2020
UTILISATION D'UN ANTICORPS CONTRE LE GANGLIOSIDE GD2 O-ACÉTYLÉ DANS LE BUT D'AMÉLIORER LE POTENTIEL THÉRAPEUTIQUE DE MÉDICAMENTS
S Birklé, J Fleurence, S Faraj, JM Le Doussal, D Cochonneau, M Terme, ...
2019
Ciblage du GD2-O-acétylé par un anticorps monoclonal dans le glioblastome multiforme
J Fleurence
Nantes, 2017
2017
Journal of Cancer Research & Therapy Volume 4, Issue 3, August 2016, Pages 21–30 Review Open Access
S Fougeray, J Fleurence, S Faraj, M Bahri, D Cochonneau, M Terme, ...
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–16